Sign In
Buy ELV
$388.50
-2.77 (-0.708%)
At Close: Jun 18, 2026
Will a Strong MA Business Aid Elevance Health's Q1 Earnings?
02:15pm, Wednesday, 16'th Apr 2025
ELV's Q1 results are expected to reap the benefits of higher premiums from growing Medicare Advantage membership and acquisitions pursued within the Carelon unit.
Ahead of Elevance Health (ELV) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:20am, Wednesday, 16'th Apr 2025
Beyond analysts' top -and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the
Elevance Health (ELV) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 15'th Apr 2025
Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility
03:06am, Sunday, 13'th Apr 2025
For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line.
Which Stocks Stayed Green as the Market Plummeted?
03:36pm, Friday, 11'th Apr 2025
Only a handful of S&P 500 stocks managed to generate gains during the market's historic four-day plunge.
GreensKeeper Q1 2025 Portfolio Update
08:55am, Thursday, 10'th Apr 2025
Berkshire Hathaway led Q1 with a 17.5% return, driven by strong operating earnings and potential for significant acquisitions with over $300 billion in cash. Vertex Pharmaceuticals gained 20.4%, fuele
US Health Insurance Stocks Rally After $25 Billion Federal Boost To Medicare Payments
11:46am, Tuesday, 08'th Apr 2025
Health insurance stocks soared Tuesday morning on the first full day of trading after the U.S. government announced a more than 5% average increase in government reimbursement rates for 2026 Medicare
Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock?
01:40pm, Friday, 04'th Apr 2025
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Thursday, 03'rd Apr 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Tuesday, 01'st Apr 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025
04:05pm, Monday, 31'st Mar 2025
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review t
Which Healthcare Stock Is the Best Buy Right Now?
07:15am, Monday, 31'st Mar 2025
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success
Elevance Trades at a Bargain: Is it a Good Time to Buy ELV Stock?
09:35am, Tuesday, 18'th Mar 2025
With a strengthening commercial business, ELV is seeing steady membership growth.
Elevance Health: Add A Little Bit Of Health To Your Defensive Portfolio
04:10am, Thursday, 13'th Mar 2025
Elevance Health remains a buy with its strong fundamentals. An added bonus is its defensive nature during the tariff wars. Regulatory changes under Trump's administration and AI integration are key fa
Strength Seen in Elevance Health (ELV): Can Its 3.1% Jump Turn into More Strength?
09:55am, Wednesday, 12'th Mar 2025
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increas
